In-vitro and in-vivo evaluation of HCV polymerase inhibitors as potential drug candidates for treatment of chronic hepatitis C infection.

被引：0
|
作者：
Dagan, S
Ilan, E
Aviel, S
Nussbaum, O
Arazi, E
Ben-Moshe, O
Slama, D
Tzionas, I
Shoshany, Y
Lee, SW
Han, JJ
Park, SJ
Lee, GH
Park, EY
Shin, JC
Suh, JW
Ji, M
Kim, JW
机构：
[1] XTL Biopharmaceut Ltd, Rehovot, Israel
[2] B&C Biopharm, Kyungki, South Korea
[3] Myong Ji Univ, Yongin, Gyunggido, South Korea
来源：
HEPATOLOGY | 2003年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
135
引用
收藏
页码：221A / 221A
页数：1
相关论文
共 50 条
  • [21] Tree shrew, a potential animal model for hepatitis C, supports the infection and replication of HCV in vitro and in vivo
    Feng, Yue
    Feng, Yue-Mei
    Lu, Caixia
    Han, Yuanyuan
    Liu, Li
    Sun, Xiaomei
    Dai, Jiejie
    Xia, Xueshan
    JOURNAL OF GENERAL VIROLOGY, 2017, 98 (08): : 2069 - 2078
  • [22] DEVELOPMENT OF FLOATING DRUG DELIVERY SYSTEM FOR LORATADINE: IN-VITRO AND IN-VIVO EVALUATION
    Sapavatu, Srinu Naik
    Jadi, Rajendra Kumar
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (06): : 3021 - 3032
  • [23] Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment: in-vitro and in-vivo evaluation
    Abdel-Wahab, Nadeen Diaa
    Kabil, Mohamed Fawzi
    El-Sherbiny, Ibrahim M.
    Salama, Mohamed F.
    El-Sayed, Gehad
    El-Sherbini, El-Said
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2024, 50 (03) : 223 - 235
  • [24] Evaluation and treatment of chronic hepatitis C infection
    Neiblum, DR
    Boynton, RF
    PRIMARY CARE, 1996, 23 (03): : 535 - +
  • [25] The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection
    Garrison, Kimberly L.
    German, Polina
    Mogalian, Erik
    Mathias, Anita
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (08) : 1212 - 1225
  • [26] In-vivo & in-vitro toxicity test of molecularly engineered PCMS: A potential drug for wireless remote controlled treatment
    Ghosh, Subrata
    Roy, Anirban
    Singhania, Anup
    Chatterjee, Somnath
    Swarnakar, Snehasikta
    Fujita, Daisuke
    Bandyopadhyay, Anirban
    TOXICOLOGY REPORTS, 2018, 5 : 1044 - 1052
  • [27] Combination treatment with pegylated interferon A and ribavirin in potential renal transplant recipients with chronic hepatitis C infection.
    Donaldson, K
    Pall, A
    Dillon, J
    Henderson, I
    Walsh, S
    SCOTTISH MEDICAL JOURNAL, 2006, 51 (01) : 55 - 55
  • [28] Risk factors for liver fibrosis in dialysis patients with chronic hepatitis C virus (HCV) infection.
    Ferreira, AS
    Perez, RM
    Lanzoni, VP
    Cendoroglo-Neto, M
    Ferraz, MLG
    Silva, AEB
    HEPATOLOGY, 2002, 36 (04) : 568A - 568A
  • [29] Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection
    Sheldon, Julie
    Barreiro, Pablo
    Soriano, Vincent
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (08) : 1171 - 1181
  • [30] Anti-p53 autoantibodies in patients with chronic hepatitis C virus (HCV) infection.
    Kallinowski, B
    Volkmann, M
    Fiehn, W
    Stremmel, W
    HEPATOLOGY, 1998, 28 (04) : 690A - 690A
12345